Distinguishing between HER2‐addicted and HER2‐nonaddicted BC, that is those responsive or not responsive to trastuzumab, could help clinicians to select HER2‐positive BC patients who are more likely to benefit from anti‐HER2 therapies in the adjuvant and metastatic settings. The gene discussed is ERBB2; the disease is breast cancer.